NexMed, Inc. (NASDAQ: NEXM)
NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product
AST WINDSOR, NJ--Jan 31, 2007 - NexMed, Inc. (NASDAQ: NEXM),
a developer of innovative transdermal treatments based on the
NexACT® drug delivery technology, today announced that its collaborator,
Novartis, has commenced dosing of patients in the Phase
3 clinical trials for NM100060, a topical treatment for onychomycosis
(nail fungus). NexMed signed an exclusive, worldwide licensing
agreement with Novartis in September 2005, under which Novartis
has assumed all clinical development, regulatory, manufacturing
and commercialization responsibilities for NM100060.
The Phase 3 program for NM100060 consists of two pivotal, randomized,
double-blind, placebo-controlled studies. The parallel
group studies are designed to assess the efficacy, safety and tolerability
of NM100060 in patients with mild to moderate toenail onychomycosis.
Approximately 1,000 patients will participate in the
two studies, which will take place in the U.S., Europe, Canada and
Iceland.
Contact NexMed, Inc.
Mark Westgate
Chief Financial Officer
mwestgate@nexmed.com
NexMed, Inc.
Paula Schwartz
Rx Communications Group, LLC
pschwartz@rxir.com
|
